Roivant's Mosliciguat Shows Record PVR Reduction in PH-ILD Trial
Event summary
- Roivant's Phase 2 PHocus study of mosliciguat in PH-ILD patients met primary and secondary endpoints, showing a 56.3% placebo-adjusted reduction in pulmonary vascular resistance (PVR).
- Secondary endpoints also met: +35.2m improvement in six-minute walk distance (6MWD) and -53.2% reduction in NT-proBNP at Week 16.
- Phase 3 PHrontier study initiated, enrolling 375 patients globally.
- Mosliciguat demonstrated favorable safety profile with lower cough incidence than placebo.
The big picture
Roivant's positive Phase 2 results position mosliciguat as a potential first-in-class treatment for PH-ILD, a rare and deadly condition with limited therapeutic options. The record PVR reduction and favorable safety profile could make it a game-changer in pulmonary hypertension treatment. The initiation of the Phase 3 trial marks a critical step toward potential commercialization in a market with significant unmet medical needs.
What we're watching
- Clinical Efficacy
- Whether mosliciguat's record PVR reduction can translate to long-term patient outcomes in the Phase 3 trial.
- Regulatory Pathway
- The pace at which Roivant can secure approvals given the unmet need in PH-ILD treatment.
- Commercial Strategy
- How Roivant positions mosliciguat against existing limited treatment options for PH-ILD.